LRRC31 to Slow Down Tumor DNA Repair in BCBM

HBI Blog / LRRC31 to Slow Down Tumor DNA Repair in BCBM

Breast cancer brain metastasis (BCBM) occurs to 10-15 percent of people, suffering from stage 4 breast cancer. BCBM’s 5 years survival rate is only 22%.

Breast cancer tumor

Radiation therapy has been a gold standard in treating tumors, but it comes with many side effects. A higher dose of radiation is an effective treatment option but poses more danger to the healthy cells.

One way to reduce the high dose of radiation in treating tumors isto slow down or stop the repair mechanism of the tumor cells.

CRISPR in action AGAIN!

LRRC31(leucine-rich repeat-containing protein 31) is a gene, developed using the gene-editing technology CRISPR, by Dr. Jiangbing Zhou at the Yale School of Medicine.

LRRC31 inhibits tumor cells’ DNA repair process and makes them more sensitive to breast cancer brain metastasis (BCBM) radiation therapy.

The translation to clinical treatment for humans might take some time, but hopefully, it is going to be one of the most effective ones.

Leave a Reply

Your email address will not be published.